Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study
Holger Eidtmann, Robert E. Coleman(Weston Park Cancer Centre), Antonio Llombart‐Cussac(Universidad Cardenal Herrera CEU), Natasha Schenk(Novartis (United States)), N. Davidson(Broomfield Hospital), Nigel Bundred(Manchester Academic Health Science Centre), Richard de Boer(Western Hospital), P. Neven(Universitair Ziekenhuis Leuven), Gϋnter von Minckwitz(German Breast group), J. Miller(Novartis (United States))
Cited by 280
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
|New England Journal of Medicine|2013|3.3k
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
|Journal of Clinical Oncology|2017|1.7k